51
|
Giuliano M, Giordano A, Hsu L, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, Hortobagyi GN, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1033] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
52
|
Guarneri V, Chavez-Mac Gregor M, Hsu L, Symmans WF, Litton JK, Mittendorf EA, Conte PF, Hortobagyi GN, Gonzalez-Angulo AM. Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
53
|
Alvarez RH, Bianchini G, Hsu L, Cristofanilli M, Esteva FJ, Pusztai L, Buzdar A, Hortobagyi GN, Valero V. The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.548] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
54
|
Giordano A, Giuliano M, Hsu L, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, Hortobagyi GN, Cristofanilli M. Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1000] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
55
|
Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol 2010; 21:2348-2355. [PMID: 20439340 DOI: 10.1093/annonc/mdq239] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC). PATIENTS AND METHODS Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (HER2) and hormone receptor status, were identified. Cumulative incidence of brain metastases was computed. Survival estimates were computed using the Kaplan-Meier product limit method. Multivariable Cox proportional hazards models were fitted to explore the relationship between breast tumor subtype and time to brain metastases. RESULTS Median follow-up was 20 months. Thirty-two (15.8%) patients developed brain metastases with a cumulative incidence at 1 and 2 years of 2.7% and 18.7%, respectively. Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 2 years of 1.6% and 5.7%, respectively. Compared with women with triple receptor-negative IBC, those with hormone receptor-positive/HER2-negative disease [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.19-1.51, P = 0.24] had a decreased risk of developing brain metastases, and those with HER2-positive disease (HR = 1.02, 95% CI 0.43-2.40, P = 0.97) had an increased risk of developing brain metastases, although these associations were not statistically significant. Median survival following a diagnosis of brain metastases was 6 months. CONCLUSION Women with newly diagnosed IBC have a high early incidence of brain metastases associated with poor survival and may be an ideal cohort to target for site-specific screening.
Collapse
|
56
|
Makar KW, Poole EM, Xiao L, Rimorin CF, Galbraith RL, Slattery ML, Duggan D, Kulmacz RJ, Koepl L, Coghill A, Hsu L, Curtain K, Muehling J, Taverna D, Caan BJ, Peters U, Carlson CS, Potter JD, Ulrich CM. Abstract 5710: COX-1 and COX-2 polymorphisms, NSAID use, and the risk of colorectal neoplasia. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-5710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce risk of colorectal adenomas and cancer. NSAIDs, including aspirin, target the prostaglandin H synthases, COX-1 and COX-2, which convert arachidonic acid into prostaglandins. We examined tagSNPs and candidate polymorphisms in COX-1 and COX-2 in relation to colorectal neoplasia risk and potential interactions with NSAID use.
Methods: A linkage-disequilibrium (LD)-based tagSNP-selection algorithm (r2=0.90, MAF=4%) identified tagSNPs in PTGS1 (COX-1) and PTGS2 (COX-2) representative of common genetic variation in Europeans. Including candidate polymorphisms, we genotyped 18 SNPs in PTGS1 and 17 SNPs in PTGS2. SNPs were genotyped on the same Illumina platform in three independent study populations that capture the range of colorectal carcinogenesis by including adenoma and cancer cases. We investigated these SNPs in relation to the risk of colorectal neoplasia and potential interactions with NSAID use in three US population-based case-control studies of colon cancer (n=1424) vs. controls (n=1780), rectal cancer (n=583) vs. controls (n=775), and colorectal adenoma (n=485) vs. controls (n=578). For single SNP associations, multiple logistic regression analysis was used, adjusting for age, sex, center and restricted to Caucasians (>90% of all study populations). No correction was made for multiple testing.
Results: There were no main associations with PTGS1 tagSNPs or candidate polymorphisms (R8W, P17L and L237M) and colorectal neoplasia risk. Although not statistically significant, the L15-L16 deletion allele showed a trend towards increased risk for both colon and rectal cancer, consistent with the previously reported increased adenoma risk. In PTGS2, a rare 5′ tagSNP (rs4648250, −1877A>G, MAF=1%) was associated with a marginally decreased risk of both rectal (OR: 0.24, 95% CI: 0.05-1.08) and colon cancer (OR: 0.63, 95% CI: 0.36-1.10).
NSAID use is known to reduce the risk of colorectal neoplasia and all three studies have shown the same protective effect in previous analyses. Interactions between genotypes and NSAID use essentially fell into one of two general categories: a) Individuals with the variant allele lost the protective effect of NSAID use (PTGS1 rs10306110-G, rectal p-interaction=0.02, adenoma p-int=0.08; PTGS2 rs689466-G, rectal p-int=0.03, colon p-int=0.18; rs20424-G, colon p-int=0.05; rs689469-A, colon p-int=0.03, rectal p-int=0.09).); and b) Individuals with the variant allele showed stronger protection with by NSAIDs than individuals with the wildtype genotype (PTGS1 rs6478565-G, rs10306135-T, rs10306164-G, rectal p-int=0.01-0.02).
Conclusion: These data suggest that a rare 5′ SNP in PTGS2 may predict risk of colorectal cancer and provide further evidence that genetic variability in PTGS1 and PTGS2 may modify the protective association between NSAID and colorectal neoplasia risk, especially for rectal cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5710.
Collapse
|
57
|
Chavez-Mac Gregor M, Vranas P, Lara J, Jackson S, Willey J, Hsu L, Ueno N, Andreopoulou E, Valero V, Lucci A, Buzdar A, Buchholz D, Hortobagyi G, Cristofanilli M. Clinical Outcomes in Two Different Cohorts of Patients with Inflammatory Breast Cancer (IBC) Treated at the MD Anderson Cancer Center: The Experience of the Morgan Welch IBC Research Program and Clinic. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Inflammatory Breast Cancer (IBC) is a rare but aggressive manifestation of primary breast cancer. Survival in patients with IBC is significantly lower than for non-IBC breast cancer patients. Appropriate diagnostic and treatment strategies provided by a specialized multidisciplinary team could impact the overall prognosis of the disease. We recently established an IBC research program and clinic including investigators from various disciplines solely dedicated to this disease. We sought to compare the characteristics and clinical outcomes of newly diagnosed IBC patients evaluated and treated using novel diagnostic and therapeutic approaches with an historical cohort of IBC patients treated at our institution.METHODS: We included 240 IBC patients treated at MD Anderson Cancer Center between January 1970 and August 2000. In this analysis we compared characteristics, 1 year progression free survival (PFS) and 1 year survival between the historic cohort and 47 patients diagnosed with IBC and seen at our IBC clinic between August 2007 and September 2008. The new patients are part of a prospective IBC registry. All of them had staging and monitoring with breast MRI and FDG-PET/CT. When indicated, they were treated with targeted therapies (e.g. trastuzumab and tipifarnib), that were not available for the patients in the old cohort. Descriptive statistics were used. Kaplan Meier product-limit method was used to calculate survival outcomes, groups were compare by log-rank test.RESULTS: Median age was similar in both cohorts (53 vs 51). In the new cohort 40% of the patients had evidence of distant metastasis at presentation. The most common sites were contralateral lymph nodes (26%), pleura (16%), bone (16%) and liver (11%). In the old cohort only 17% presented with stage IV. 38.7% of the new patients had Her2-neu amplified and 34%, triple receptor negative IBC. There was no difference in 1-year survival between the two groups (92.4% vs. 93.8%, p=0.637). For patients with stage III disease, the 1-year survival was 95% for both groups. The 1 year-PFS was 86.4% in the new cohort compared to 77.9% (p=0.43) in the old cohort. With a median follow up of 13 months, 51%of the patients in the new cohort are disease free and 87% are still alive.CONCLUSIONS: IBC is an aggressive but rare disease with poor prognosis. We have established a specialized IBC research program and clinic that introduces novel concepts and strategies in laboratory, imaging diagnostics and targeted therapies. This approach may accelerate our understanding of the biology, develop new therapeutic strategies and finally improve the outcome of IBC. Early results of this multidisciplinary approach show a modest, but not significant difference in outcome. We hope that with additional patients and longer follow-up a significant improvement in outcomes will become apparent.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5119.
Collapse
|
58
|
Mego M, Mego M, Mego M, De Giorgi U, De Giorgi U, Hsu L, Dawood S, Andreoupolou E, Valero V, Handy B, Ueno N, Reuben J, Cristofanilli M. Predictive Value of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer Patients Treated by Bevacizumab-Based Therapy. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Circulating tumor cells (CTC) are involved in cancer dissemination and are an independent prognostic factor in metastatic breast cancer (MBC). Antiangiogenic, bevacizumab-based chemotherapy improves response rate and progression free survival in patients with metastatic breast cancer (MBC), without impact on overall survival. Preclinical data suggest the possibility of increased metastatic potential of tumor cells pretreated by anti-angiogenic therapy (Ebos et al. Cancer Cell 2009,15: 232–9). The aim of this study was to determine the prognostic value of CTC in MBC patients treated by bevacizumab-based therapy.Patients and Methods: This retrospective study included 48 MBC treated with bevacizumab combined chemotherapy regimens and 46 patients treated with chemotherapy alone between January 2004 and December 2008 at M.D.Anderson Cancer Center. CTCs were detected and enumerated before patients started therapy using the CellSearch™ system (Veridex, LLC, NJ, USA). Progression free survival (PFS) and overall survival (OS) were calculated from the date of CTC measurement, estimated by the Kaplan-Meier product limit method, and compared between groups with the log-rank test.Results: At a median follow up of 10.1 months (range: 1-26 months), 22 patients (45.8%) had died. The estimated medians of PFS in bevacizumab-treated patients were 8.1 vs. 5.2 months (p = 0.42) in patients with baseline < 5 CTCs vs. ≥ 5 CTCs. Moreover, the OS for the two subgroups were 18.3 vs. 12.4 months (p = 0.41), respectively. Twenty-three patients had CTC measurements at the time of progression. Median CTC counts at baseline and at time of disease progression were 6 (range: 0-230) and 7 (range: 0-359) respectively in the bevacizumab-treated group. The median CTC counts in the control group at same time points were 7 (range: 0-724) and 2 (range:0-999), respectively. Thirteen (56.5%) and 12 (52.2%) patients had CTC ≥ 5 at baseline and at time of disease progression in bevacizumab-treated group compared to CTC counts of 24 (52.2%) and 17 (37%) in control group treated with chemotherapy without bevacizumab. Post progression overall survival in patients with CTC < 5 and CTC ≥ 5 measured at time of disease progression were 11.0 and 10.4 months (p = 0.36), in the bevacizumab treated group vs. 27 and 12.4 months (p = 0.04), in the control group respectively.Conclusion: Our data support the prognostic value of CTC measured before therapy in MBC. The detection of higher CTC counts at time of disease progression and the limited prognostic value of CTC after failure of bevacizumab-based chemotherapy although intriguing, warrants further prospective investigations. Moreover, a comparison between the differential effects of monoclonal antibodies and tyrosine kinases inhibitors on CTCs detection and monitoring will better clarify the role of specific targeted therapies on micrometastatic disease.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3013.
Collapse
|
59
|
Dawood S, Ueno N, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz T, Hortobagyi G, Cristofanilli M. Brain Metastases in Women with Inflammatory Breast Cancer (IBC): Incidence, Treatment and Outcome. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-2102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Brain metastases are an uncommon metastatic recurrence site in breast cancer with a median incidence of approximately 6% in unselected populations. Inflammatory breast cancer (IBC) is an aggressive disease associated with dismal outcome. The purpose of this study was to determine the incidence of and survival following brain metastases among women with IBC.Material and Methods: Two hundred and six women with newly diagnosed stage III or IV IBC diagnosed between the period of between 2003 and 2008 were identified in a prospectively maintained IBC database at the MD Anderson Cancer Center. Cumulative incidence of brain metastases was computed. Cox proportional hazards models were fitted to explore factors that predict for the development of brain metastases. Survival was computed using the Kaplan-Meier product limit method.Results: Median follow-up was 20 months. Eighty three (40.3%) women had de-novo stage IV disease and 123 (59.7%) had stage III disease at diagnosis. Thirty-three (16%) patients developed brain metastases with a cumulative incidence at 1 and 3 years of 2.7% and 22% respectively. Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 3 years of 1.6% and 6.7% respectively. In the multivariable model, no specific factor was observed to be significantly associated with time to brain metastases, including HER-2 status. Median overall survival for the whole cohort was not reached. 3-year overall survival for the whole cohort was 78% (95% CI 69%-86%). Median survival following a diagnosis of brain metastases for all women who developed brain metastases or those who developed brain metastases as the first site of recurrence was 6 months.Conclusion: In this single-institutional study, women with IBC demonstrated a high early incidence of brain metastases associated with poor survival. As such IBC may be an ideal cohort to target screening procedures for brain metastases and/or enrollment of these women in clinical trials evaluating additional adjuvant preventive strategies.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2102.
Collapse
|
60
|
Mego M, De Giorgi U, Hsu L, Ueno N, Valero V, Jackson S, Andreopoulou E, Kau SW, Reuben J, Cristofanilli M. Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol 2009; 20:1824-8. [DOI: 10.1093/annonc/mdp207] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
|
61
|
Ahmed Z, Akerib DS, Arrenberg S, Bailey CN, Balakishiyeva D, Baudis L, Bauer DA, Beaty J, Brink PL, Bruch T, Bunker R, Cabrera B, Caldwell DO, Cooley J, Cushman P, Dejongh F, Dragowsky MR, Duong L, Figueroa-Feliciano E, Filippini J, Fritts M, Golwala SR, Grant DR, Hall J, Hennings-Yeomans R, Hertel S, Holmgren D, Hsu L, Huber ME, Kamaev O, Kiveni M, Kos M, Leman SW, Mahapatra R, Mandic V, Moore D, McCarthy KA, Mirabolfathi N, Nelson H, Ogburn RW, Pyle M, Qiu X, Ramberg E, Rau W, Reisetter A, Saab T, Sadoulet B, Sander J, Schnee RW, Seitz DN, Serfass B, Sundqvist KM, Tarka M, Wang G, Yellin S, Yoo J, Young BA. Search for axions with the CDMS experiment. PHYSICAL REVIEW LETTERS 2009; 103:141802. [PMID: 19905561 DOI: 10.1103/physrevlett.103.141802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2009] [Indexed: 05/28/2023]
Abstract
We report on the first axion search results from the Cryogenic Dark Matter Search (CDMS) experiment at the Soudan Underground Laboratory. An energy threshold of 2 keV for electron-recoil events allows a search for possible solar axion conversion into photons or local galactic axion conversion into electrons in the germanium crystal detectors. The solar axion search sets an upper limit on the Primakov coupling g(agammagamma) of 2.4x10(-9) GeV-1 at the 95% confidence level for an axion mass less than 0.1 keV/c2. This limit benefits from the first precise measurement of the absolute crystal plane orientations in this type of experiment. The galactic axion search analysis sets a world-leading experimental upper limit on the axioelectric coupling g(aee) of 1.4x10(-12) at the 90% confidence level for an axion mass of 2.5 keV/c2.
Collapse
|
62
|
Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009; 20:1953-8. [PMID: 19596702 DOI: 10.1093/annonc/mdp263] [Citation(s) in RCA: 220] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND We evaluated discordance in expression measurements for estrogen receptor (ER), progesterone receptor (PR), and HER2 between primary and recurrent tumors in patients with recurrent breast cancer and its effect on prognosis. METHODS A total of 789 patients with recurrent breast cancer were studied. ER, PR, and HER2 status were determined by immunohistochemistry (IHC) and/or FISH. Repeat markers for ER, PR, and HER2 were available in 28.9%, 27.6%, and 70.0%, respectively. Primary and recurrent tumors were classified as triple receptor-negative breast cancer (TNBC) or receptor-positive breast cancer (RPBC, i.e. expressing at least one receptor). Discordance was correlated with clinical/pathological parameters. RESULTS Discordance for ER, PR, and HER2 was 18.4%, 40.3%, and 13.6%, respectively. Patients with concordant RPBC had significantly better post-recurrence survival (PRS) than discordant cases; patients with discordant receptor status had similarly unfavorable survival as patients with concordant TNBC. IHC scores for ER and PR showed weak concordance between primary and recurrent tumors. Concordance of HER2-FISH scores was higher. CONCLUSIONS Concordance of quantitative hormone receptor measurements between primary and recurrent tumors is modest consistent with suboptimal reproducibility of measurement methods, particularly for IHC. Discordant cases have poor survival probably due to inappropriate use of targeted therapies. However, biological change in clinical phenotype cannot be completely excluded.
Collapse
|
63
|
Mego M, De Giorgi U, Hsu L, Andreopoulou E, Valero V, Dawood S, Handy B, Reuben JM, Cristofanilli M. Circulating tumor cells and risk of venous thromboembolism in metastatic breast cancer patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1060 Background: Cancer is well-recognized risk factor for venous thromboembolism (VTE), and VTE is associated with a higher risk of death in cancer patients. Coagulation activation by tissue factor (TF) is associated with cancer growth and disease progression. Circulating tumor cells (CTCs) are an independent predictor of survival in metastatic breast cancer (MBC) patients. The aim of this study was to test the hypothesis that CTCs are associated with the risk of VTE in MBC patients. Methods: This retrospective study included 362 MBC patients treated in M. D. Anderson Cancer Center between January 2004 and December 2007. CTCs were detected and enumerated using the CellSearch system. Patients were assigned to cohorts based on the highest CTC counts during the course of the disease. All venous thrombosis and/or pulmonary embolism in the presence of unequivocal medical documentation were classified as events. Results: At a median follow up of 11.1 months (range 0–38 months) 30 patients (8.3%) experienced VTE. Median survival was 16.3 months vs. 37.2 months (p = 0.003) in patients with and without VTE, respectively. Patients with ≥ 3 CTCs had an elevated risk of VTE in comparison to patients with < 3 CTCs (12.1% vs 3.7%; p = 0.003). In multivariate analysis, the presence of visceral metastasis, increased number of metastatic sites and ≥ 3 CTCs were associated with the risk of VTE. Conclusions: This retrospective study showed that CTCs are associated with increased risk of VTE in MBC. Prospective assessment of coagulation status and its correlation to CTC counts and clinical outcome are warranted. No significant financial relationships to disclose.
Collapse
|
64
|
Waters MS, El-Naggar MY, Hsu L, Sturm CA, Luttge A, Udwadia FE, Cvitkovitch DG, Goodman SD, Nealson KH. Simultaneous interferometric measurement of corrosive or demineralizing bacteria and their mineral interfaces. Appl Environ Microbiol 2009; 75:1445-9. [PMID: 19124590 PMCID: PMC2648148 DOI: 10.1128/aem.02039-08] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2008] [Accepted: 12/26/2008] [Indexed: 11/20/2022] Open
Abstract
Here, we report simultaneous surface profile measurements of several bacterial species involved in microbially influenced corrosion and their solid-surface interfaces by using vertical scanning interferometry. The capacity to nondestructively quantify microscale topographic changes beneath a single bacterium without its removal offers a unique opportunity to examine in vivo microbe-surface interactions.
Collapse
|
65
|
De Sciscio P, Sacher F, Jaïs P, Brooks A, Hsu L, Hocini M, Haïssaguerre M, Sanders P. Stretch Related Pulmonary Vein Remodelling in Humans. Heart Lung Circ 2009. [DOI: 10.1016/j.hlc.2009.05.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
66
|
Loo LWM, Ton C, Wang YW, Grove DI, Bouzek H, Vartanian N, Lin MG, Yuan X, Lawton TL, Daling JR, Malone KE, Li CI, Hsu L, Porter PL. Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes Chromosomes Cancer 2008; 47:1049-66. [PMID: 18720524 DOI: 10.1002/gcc.20610] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
The two main histological types of infiltrating breast cancer, lobular (ILC) and the more common ductal (IDC) carcinoma are morphologically and clinically distinct. To assess the molecular alterations associated with these breast cancer subtypes, we conducted a whole-genome study of 166 archival estrogen receptor (ER)-positive tumors (89 IDC and 77 ILC) using the Affymetrix GeneChip(R) Mapping 10K Array to identify sites of loss of heterozygosity (LOH) that either distinguished, or were shared by, the two phenotypes. We found single nucleotide polymorphisms (SNPs) of high-frequency LOH (>50%) common to both ILC and IDC tumors predominately in 11q, 16q, and 17p. Overall, IDC had a slightly higher frequency of LOH events across the genome than ILC (fractional allelic loss = 0.186 and 0.156). By comparing the average frequency of LOH by chromosomal arm, we found IDC tumors with significantly (P < 0.05) higher frequency of LOH on 3p, 5q, 8p, 9p, 20p, and 20q than ILC tumors. We identified additional chromosomal arms differentiating the subtypes when tumors were stratified by tumor size, mitotic rate, or DNA content. Of 5,754 informative SNPs (>25% informativity), we identified 78 and 466 individual SNPs with a higher frequency of LOH (P < 0.05) in ILC and IDC tumors, respectively. Hierarchical clustering of these 544 SNPs grouped tumors into four major groups based on their patterns of LOH and retention of heterozygosity. LOH in chromosomal arms 8p and 5q was common in higher grade IDC tumors, whereas ILC and low-grade IDC grouped together by virtue of LOH in 16q.
Collapse
|
67
|
Adamson P, Andreopoulos C, Arms KE, Armstrong R, Auty DJ, Ayres DS, Backhouse C, Baller B, Barr G, Barrett WL, Becker BR, Belias A, Bernstein RH, Bhattacharya D, Bishai M, Blake A, Bock GJ, Boehm J, Boehnlein DJ, Bogert D, Bower C, Buckley-Geer E, Cavanaugh S, Chapman JD, Cherdack D, Childress S, Choudhary BC, Cobb JH, Coleman SJ, Culling AJ, de Jong JK, Dierckxsens M, Diwan MV, Dorman M, Dytman SA, Escobar CO, Evans JJ, Harris EF, Feldman GJ, Frohne MV, Gallagher HR, Godley A, Goodman MC, Gouffon P, Gran R, Grashorn EW, Grossman N, Grzelak K, Habig A, Harris D, Harris PG, Hartnell J, Hatcher R, Heller K, Himmel A, Holin A, Hsu L, Hylen J, Irwin GM, Ishitsuka M, Jaffe DE, James C, Jensen D, Kafka T, Kasahara SMS, Kim JJ, Kim MS, Koizumi G, Kopp S, Kordosky M, Koskinen DJ, Kotelnikov SK, Kreymer A, Kumaratunga S, Lang K, Ling J, Litchfield PJ, Litchfield RP, Loiacono L, Lucas P, Ma J, Mann WA, Marchionni A, Marshak ML, Marshall JS, Mayer N, McGowan AM, Meier JR, Messier MD, Metelko CJ, Michael DG, Miller WH, Mishra SR, Moore CD, Morfín J, Mualem L, Mufson S, Murgia S, Musser J, Naples D, Nelson JK, Newman HB, Nichol RJ, Nicholls TC, Ochoa-Ricoux JP, Oliver WP, Ospanov R, Paley J, Paolone V, Para A, Patzak T, Pavlović Z, Pawloski G, Pearce GF, Peck CW, Petyt DA, Pittam R, Plunkett RK, Rahaman A, Rameika RA, Raufer TM, Rebel B, Reichenbacher J, Rodrigues PA, Rosenfeld C, Rubin HA, Ryabov VA, Sanchez MC, Saoulidou N, Schneps J, Schreiner P, Shanahan P, Smart W, Smith C, Sousa A, Speakman B, Stamoulis P, Strait M, Tagg N, Talaga RL, Tavera MA, Thomas J, Thomson MA, Thron JL, Tinti G, Trostin I, Tsarev VA, Tzanakos G, Urheim J, Vahle P, Viren B, Ward DR, Watabe M, Weber A, Webb RC, Wehmann A, West N, White C, Wojcicki SG, Wright DM, Yang T, Zhang K, Zwaska R. Search for active neutrino disappearance using neutral-current interactions in the MINOS long-baseline experiment. PHYSICAL REVIEW LETTERS 2008; 101:221804. [PMID: 19113477 DOI: 10.1103/physrevlett.101.221804] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2008] [Indexed: 05/27/2023]
Abstract
We report the first detailed comparisons of the rates and spectra of neutral-current neutrino interactions at two widely separated locations. A depletion in the rate at the far site would indicate mixing between nu(mu) and a sterile particle. No anomalous depletion in the reconstructed energy spectrum is observed. Assuming oscillations occur at a single mass-squared splitting, a fit to the neutral- and charged-current energy spectra limits the fraction of nu(mu) oscillating to a sterile neutrino to be below 0.68 at 90% confidence level. A less stringent limit due to a possible contribution to the measured neutral-current event rate at the far site from nu(e) appearance at the current experimental limit is also presented.
Collapse
|
68
|
Lu MF, Lee D, Carlson R, Rao GS, Hui HW, Adjei L, Herrin M, Sundberg D, Hsu L. The Effects of Formulation Variables on Iontophoretic Transdermal Delivery of Leuprolide to Humans. Drug Dev Ind Pharm 2008. [DOI: 10.3109/03639049309069326] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
69
|
Abe S, Ebihara T, Enomoto S, Furuno K, Gando Y, Ichimura K, Ikeda H, Inoue K, Kibe Y, Kishimoto Y, Koga M, Kozlov A, Minekawa Y, Mitsui T, Nakajima K, Nakajima K, Nakamura K, Nakamura M, Owada K, Shimizu I, Shimizu Y, Shirai J, Suekane F, Suzuki A, Takemoto Y, Tamae K, Terashima A, Watanabe H, Yonezawa E, Yoshida S, Busenitz J, Classen T, Grant C, Keefer G, Leonard DS, McKee D, Piepke A, Decowski MP, Detwiler JA, Freedman SJ, Fujikawa BK, Gray F, Guardincerri E, Hsu L, Kadel R, Lendvai C, Luk KB, Murayama H, O'Donnell T, Steiner HM, Winslow LA, Dwyer DA, Jillings C, Mauger C, McKeown RD, Vogel P, Zhang C, Berger BE, Lane CE, Maricic J, Miletic T, Batygov M, Learned JG, Matsuno S, Pakvasa S, Foster J, Horton-Smith GA, Tang A, Dazeley S, Downum KE, Gratta G, Tolich K, Bugg W, Efremenko Y, Kamyshkov Y, Perevozchikov O, Karwowski HJ, Markoff DM, Tornow W, Heeger KM, Piquemal F, Ricol JS. Precision measurement of neutrino oscillation parameters with KamLAND. PHYSICAL REVIEW LETTERS 2008; 100:221803. [PMID: 18643415 DOI: 10.1103/physrevlett.100.221803] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/29/2008] [Indexed: 05/26/2023]
Abstract
The KamLAND experiment has determined a precise value for the neutrino oscillation parameter Deltam21(2) and stringent constraints on theta12. The exposure to nuclear reactor antineutrinos is increased almost fourfold over previous results to 2.44 x 10(32) proton yr due to longer livetime and an enlarged fiducial volume. An undistorted reactor nu[over]e energy spectrum is now rejected at >5sigma. Analysis of the reactor spectrum above the inverse beta decay energy threshold, and including geoneutrinos, gives a best fit at Deltam21(2)=7.58(-0.13)(+0.14)(stat) -0.15+0.15(syst) x 10(-5) eV2 and tan2theta12=0.56(-0.07)+0.10(stat) -0.06+0.10(syst). Local Deltachi2 minima at higher and lower Deltam21(2) are disfavored at >4sigma. Combining with solar neutrino data, we obtain Deltam21(2)=7.59(-0.21)+0.21 x 10(-5) eV2 and tan2theta12=0.47(-0.05)+0.06.
Collapse
|
70
|
Ibrahim NK, Abdulkarim B, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R. A nomogram to predict subsequent brain metastasis in metastatic breast cancer (MBC) patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
71
|
Broglio K, Moulder SL, Hsu L, Kau S, Pusztai L, Symmans WF, Hortobagyi GN, Gonzalez-Angulo AM, Liedtke C. Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
72
|
Lieber E, Hsu L, Spitler L, Fudenberg HH. Cytogenetic findings in a parent of a patient with Fanconi's anemia. Clin Genet 2008; 3:357-63. [PMID: 5084382 DOI: 10.1111/j.1399-0004.1972.tb01468.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
73
|
Cohen GL, Sherman DK, Bastardi A, Hsu L, McGoey M, Ross L. Bridging the partisan divide: Self-affirmation reduces ideological closed-mindedness and inflexibility in negotiation. J Pers Soc Psychol 2007; 93:415-30. [PMID: 17723057 DOI: 10.1037/0022-3514.93.3.415] [Citation(s) in RCA: 153] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Three studies link resistance to probative information and intransigence in negotiation to concerns of identity maintenance. Each shows that affirmations of personal integrity (vs. nonaffirmation or threat) can reduce resistance and intransigence but that this effect occurs only when individuals' partisan identity and/or identity-related convictions are made salient. Affirmation made participants' assessment of a report critical of U.S. foreign policy less dependent on their political views, but only when the identity relevance of the issue rather than the goal of rationality was salient (Study 1). Affirmation increased concession making in a negotiation over abortion policy, but again this effect was moderated by identity salience (Studies 2 and 3). Indeed, although affirmed negotiators proved relatively more open to compromise when either the salience of their true convictions or the importance of remaining faithful to those convictions was heightened, the reverse was true when the salient goal was compromise. The theoretical and applied significance of these findings are discussed.
Collapse
|
74
|
Bornheim A, Lipeles E, Pappas SP, Shapiro A, Sun WM, Weinstein AJ, Briere RA, Chen GP, Ferguson T, Tatishvili G, Vogel H, Adam NE, Alexander JP, Berkelman K, Blanc F, Boisvert V, Cassel DG, Drell PS, Duboscq JE, Ecklund KM, Ehrlich R, Galik RS, Gibbons L, Gittelman B, Gray SW, Hartill DL, Heltsley BK, Hsu L, Jones CD, Kandaswamy J, Kreinick DL, Magerkurth A, Mahlke-Kruger H, Meyer TO, Mistry NB, Patterson JR, Peterson D, Pivarski J, Richichi SJ, Riley D, Sadoff AJ, Schwarthoff H, Shepherd MR, Thayer JG, Urner D, Wilksen T, Warburton A, Weinberger M, Athar SB, Avery P, Breva-Newell L, Potlia V, Stoeck H, Yelton J, Benslama K, Eisenstein BI, Gollin GD, Karliner I, Lowrey N, Plager C, Sedlack C, Selen M, Thaler JJ, Williams J, Edwards KW, Besson D, Zhao X, Anderson S, Frolov VV, Gong DT, Kubota Y, Li SZ, Poling R, Smith A, Stepaniak CJ, Urheim J, Metreveli Z, Seth KK, Tomaradze A, Zweber P, Ahmed S, Alam MS, Ernst J, Jian L, Saleem M, Wappler F, Arms K, Eckhart E, Gan KK, Gwon C, Honscheid K, Hufnagel D, Kagan H, Kass R, Pedlar TK, von Toerne E, Zoeller MM, Severini H, Skubic P, Dytman SA, Mueller JA, Nam S, Savinov V, Hinson JW, Lee J, Miller DH, Pavlunin V, Sanghi B, Shibata EI, Shipsey IPJ, Cronin-Hennessy D, Lyon AL, Park CS, Park W, Thayer JB, Thorndike EH, Coan TE, Gao YS, Liu F, Maravin Y, Stroynowski R, Artuso M, Boulahouache C, Blusk S, Bukin K, Dambasuren E, Mountain R, Muramatsu H, Nandakumar R, Skwarnicki T, Stone S, Wang JC, Mahmood AH, Csorna SE, Danko I, Bonvicini G, Cinabro D, Dubrovin M, McGee S. Publisher’s Note: Measurements of charmless hadronic two-bodyBmeson decays and the ratioB(B→DK)/B(B→Dπ)[Phys. Rev. D68, 052002 (2003)]. Int J Clin Exp Med 2007. [DOI: 10.1103/physrevd.75.119907] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
75
|
Nakamura M, Nestor PG, McCarley RW, Levitt JJ, Hsu L, Kawashima T, Niznikiewicz M, Shenton ME. Altered orbitofrontal sulcogyral pattern in schizophrenia. Brain 2007; 130:693-707. [PMID: 17347256 PMCID: PMC2768130 DOI: 10.1093/brain/awm007] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Orbitofrontal alteration in schizophrenia has not been well characterized, likely due to marked anatomical variability. To investigate the presence of such alterations, we evaluated the sulcogyral pattern of this 'H-shaped' sulcus. Fifty patients with schizophrenia (100 hemispheres) and 50 age- and gender-matched control subjects (100 hemispheres) were evaluated using 3D high-spatial resolution MRI. Based on a previous study by Chiavaras and Petrides (2000), the sulcogyral pattern of the 'H-shaped' sulcus, which forms the boundaries of major orbitofrontal gyri, was classified into three types (Type I, II and III, in order of frequency) within each hemisphere. Chi-square analysis was performed to compare the sulcogyral pattern, and categorical regression was applied to investigate clinical/cognitive associations. The control data replicated the orbitofrontal sulcogyral pattern reported by Chiavaras and Petrides (P = 0.90-0.95), where the distribution was significantly different between the left and right hemisphere (Type I: right > left, Type II, III: left > right, chi2 = 6.41, P = 0.041). For schizophrenics, the distribution differed significantly from controls (chi2 = 11.90, P = 0.003), especially in the right hemisphere (chi2 = 13.67, P = 0.001). Moreover, the asymmetry observed in controls was not present in schizophrenia (chi2 = 0.13, P = 0.94). Specifically, the most frequent Type I expression was decreased and the rarest Type III expression was increased in schizophrenia, relative to controls. Furthermore, patients with Type III expression in any hemisphere evinced poorer socioeconomic status, poorer cognitive function, more severe symptoms and impulsivity, compared to patients without Type III expression. In contrast, patients with Type I in any hemisphere showed better cognitive function and milder symptoms compared to patients without Type I. Structurally, patients with Type III had significantly smaller intra-cranial contents (ICC) volumes than did patients without Type III (t(40) = 2.29, P = 0.027). The present study provides evidence of altered distribution of orbitofrontal sulcogyral pattern in schizophrenia, possibly reflecting a neurodevelopmental aberration in schizophrenia. Such altered sulcogyral pattern is unlikely to be due to secondary effects of the illness such as medication. Moreover, the structural association between Type III and small ICC volume, observed in the patient group, may suggest that Type III expression could be part of a systematic neurodevelopmental alteration, given that the small ICC volume could reflect early reduction of cranial growth driven by brain growth. The observed contrasting association of Type III expression with poorer outcome, and that of Type I expression with better outcome, further suggests clinical heterogeneity, and possible differences in treatment responsiveness in schizophrenia.
Collapse
|